Sonoma Pharmaceuticals Net Worth
Sonoma Pharmaceuticals Net Worth Breakdown | SNOA |
Sonoma Pharmaceuticals Net Worth Analysis
Sonoma Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Sonoma Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Sonoma Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Sonoma Pharmaceuticals' net worth analysis. One common approach is to calculate Sonoma Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Sonoma Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Sonoma Pharmaceuticals' net worth. This approach calculates the present value of Sonoma Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Sonoma Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Sonoma Pharmaceuticals' net worth. This involves comparing Sonoma Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Sonoma Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Sonoma Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Sonoma Pharmaceuticals' net worth research are outlined below:
| Sonoma Pharmaceuticals is way too risky over 90 days horizon | |
| Sonoma Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Sonoma Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 14.29 M. Net Loss for the year was (3.46 M) with profit before overhead, payroll, taxes, and interest of 5.46 M. | |
| Sonoma Pharmaceuticals currently holds about 5.59 M in cash with (88 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.8. | |
| Latest headline from prnewswire.com: Sonomas Griffo Distillery earns Americas Greatest London Dry Gin |
Sonoma Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Sonoma Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Sonoma Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 19th of June 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 19th of June 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of March 2023 Last Financial Announcement | View |
Know Sonoma Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Sonoma Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sonoma Pharmaceuticals backward and forwards among themselves. Sonoma Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Sonoma Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ground Swell Capital, Llc | 2024-12-31 | 0.0 | Wells Fargo & Co | 2024-12-31 | 0.0 | Advisor Group Holdings, Inc. | 2025-03-31 | 0.0 | Ubs Group Ag | 2024-12-31 | 17.4 K | Geode Capital Management, Llc | 2025-03-31 | 16.8 K | Hrt Financial Llc | 2025-03-31 | 11.8 K | Tower Research Capital Llc | 2025-03-31 | 1.4 K | Citigroup Inc | 2025-03-31 | 811 | Jpmorgan Chase & Co | 2025-03-31 | 138 | Blackrock Inc | 2025-03-31 | 113 | U.s. Bancorp | 2025-03-31 | 25.0 |
Follow Sonoma Pharmaceuticals' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.71 M.Market Cap |
|
Project Sonoma Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.25) | (0.27) | |
| Return On Capital Employed | (0.39) | (0.41) | |
| Return On Assets | (0.25) | (0.27) | |
| Return On Equity | (0.78) | (0.74) |
When accessing Sonoma Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Sonoma Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Sonoma Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the presentation of Sonoma Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Sonoma Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Sonoma Pharmaceuticals' management manipulating its earnings.
Evaluate Sonoma Pharmaceuticals' management efficiency
Sonoma Pharmaceuticals has return on total asset (ROA) of (0.1631) % which means that it has lost $0.1631 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6555) %, meaning that it created substantial loss on money invested by shareholders. Sonoma Pharmaceuticals' management efficiency ratios could be used to measure how well Sonoma Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of June 27, 2025, Return On Tangible Assets is expected to decline to -0.27. In addition to that, Return On Capital Employed is expected to decline to -0.41. At present, Sonoma Pharmaceuticals' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 1.8 M, whereas Total Current Assets are forecasted to decline to about 12.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.55 | 3.38 | |
| Tangible Book Value Per Share | 3.55 | 3.38 | |
| Enterprise Value Over EBITDA | 0.66 | 0.69 | |
| Price Book Value Ratio | 0.62 | 0.65 | |
| Enterprise Value Multiple | 0.66 | 0.69 | |
| Price Fair Value | 0.62 | 0.65 | |
| Enterprise Value | 13.9 M | 13.2 M |
The management team at Sonoma Pharmaceuticals has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Enterprise Value Revenue 0.1412 | Revenue | Quarterly Revenue Growth 0.092 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sonoma Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sonoma Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sonoma Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mclaughlin John over six months ago Acquisition by Mclaughlin John of 20000 shares of Sonoma Pharmaceuticals at 1.08 subject to Rule 16b-3 | ||
Schutz James J over six months ago Disposition of 28 shares by Schutz James J of Sonoma Pharmaceuticals at 70.35 subject to Rule 16b-3 | ||
Dal Poggetto John over a year ago Acquisition by Dal Poggetto John of 15000 shares of Sonoma Pharmaceuticals subject to Rule 16b-3 | ||
Dal Poggetto John over a year ago Disposition of 1648 shares by Dal Poggetto John of Sonoma Pharmaceuticals at 175.5 subject to Rule 16b-3 | ||
Frederick Sandford over a year ago Acquisition by Frederick Sandford of 400000 shares of Sonoma Pharmaceuticals at 0.717 subject to Rule 16b-3 | ||
Bruce Thornton over a year ago Acquisition by Bruce Thornton of 60000 shares of Sonoma Pharmaceuticals subject to Rule 16b-3 | ||
Bruce Thornton over a year ago Acquisition by Bruce Thornton of 100000 shares of Sonoma Pharmaceuticals subject to Rule 16b-3 |
Sonoma Pharmaceuticals Corporate Filings
F4 | 20th of June 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10K | 17th of June 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 28th of April 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 5th of February 2025 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Sonoma Pharmaceuticals Earnings per Share Projection vs Actual
Sonoma Pharmaceuticals Corporate Management
| Jerome Dvonch | Interim Officer | Profile | |
| John Poggetto | Controller | Profile | |
| Jerome CPA | Chief Officer | Profile | |
| Victoria Covel | Assistant Controller | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonoma Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonoma Pharmaceuticals. If investors know Sonoma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonoma Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.79) | Revenue Per Share | Quarterly Revenue Growth 0.092 | Return On Assets | Return On Equity |
The market value of Sonoma Pharmaceuticals is measured differently than its book value, which is the value of Sonoma that is recorded on the company's balance sheet. Investors also form their own opinion of Sonoma Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Sonoma Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonoma Pharmaceuticals' market value can be influenced by many factors that don't directly affect Sonoma Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonoma Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonoma Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonoma Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.